胆 - 石榴 (CAGE) 离子液体增强基药物的抗癌活性
Marta Costa Verdugo1,2,3, Giulia Sierri3, Laura Hernandez-Fernandez1,2
1Donostia International Physics Center (DIPC), Donostia-San Sebastián, Euskadi, Spain. lsalassa@dipc.org.
概括
基于胆和基兰酸的离子液体 (CAGE ILs) 增强了白金抗癌药物的疗效. 与CAGE IL配制的复合物3显著促进了质母细胞瘤细胞死亡,显示出有前途的治疗潜力.
科学领域:
- 药用化学 医学化学
- 纳米技术 纳米技术
- 在瘤学瘤学.
背景情况:
- (II) 和 (IV) 复合物是重要的抗癌剂.
- 离子液体 (ILs) 为药物配方和输送提供独特的特性.
- 基于胆和基兰酸的离子液体 (CAGE ILs) 构成了一种新的IL类.
研究的目的:
- 研究CAGE ILs对Pt(II) 和Pt(IV) 复合物的溶解性和抗癌活性的影响.
- 为了评估CAGE ILs.中的一种疏水性衍生物的稳定性和细胞局部化.
- 评估CAGE ILs和复合体对U87-MG质母细胞瘤细胞的协同作用.
主要方法:
- 合成和表征Pt (II) 和Pt (IV) 复合体.
- 在 CAGE ILs 中复合物的可溶性研究.
- 在CAGE ILs.中对疏水性衍生物的稳定性评估.
- F-H HOESY NMR用于细胞局部化研究.
- 在体外细胞毒性测定使用U87-MG质母细胞瘤细胞.
主要成果:
- 所有研究的复合物都在CAGE ILs中显示出良好的溶解性.
- 疏水性衍生物 (复合物3) 在CAGE ILs中表现出显著的稳定性,长达48小时.
- F-H HOESY NMR证实了复合体3在CAGE 1:2 (胆:石榴) 的疏水区域内的局部化.
- CAGE ILs显著增强了复合体对U87-MG细胞的抗癌活性.
- 与CAGE IL配制的复合3表明细胞毒性大幅增加,几乎消除了细胞活力.
结论:
- ILs可以有效地溶解和稳定抗癌剂.
- 复合物的配方,特别是疏水衍生物,与CAGE IL增强了它们的抗癌功效.
- CAGE ILs显示出作为改善基化疗治疗质母细胞瘤的药物输送载体的潜力.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K


